As biopharmaceutical companies strive to manage development costs, gather dose range data sooner, accelerate development timelines, and obtain earlier efficacy signals, PAREXEL helps meet these multiple goals in early stage development. PAREXEL's early phase services provide fully integrated solutions from First in Man through Proof-of-Concept and help biopharmaceutical companies seeking to return solid, reproducible outcomes to succeed in later-phase trials.
PAREXEL's early phase units are located across three continents, including in Baltimore and Los Angeles in the United States; London, United Kingdom; Berlin, Germany; and Bloemfontein, George, and Port Elizabeth, South Africa. PAREXEL's early phase capabilities include a full scope of early phase studies, specialized trial design, state-of-the-art technologies, hospital-based resources, and scientific expertise as well as vast experience in the oncology, neurology, cardiology, respiratory, and metabolism/endocrine therapeutic areas. For more information about PAREXEL's early phase capabilities visit: http://www.PAREXEL.com/Early_Phase.html.
About PAREXEL International PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug de
|SOURCE PAREXEL International Corporation|
Copyright©2010 PR Newswire.
All rights reserved